Pricing

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

By

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Insurers struggle with Sovaldi angst

A report indicates that Sovaldi's high price may hurt health-insurance investors.

ASCO will grade drugs

The professional association says it's necessary, because high prices do not indicate impact.

NICE says no to Xofigo, Zaltrap

NICE says no to Xofigo, Zaltrap

By

The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.

Sovaldi price worries states

Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.

NICE wants more Soliris information

The UK watchdog wants to know what's behind the rare-disease drug's high price.

Industry wary of new German pricing rule

Germany's price transparency requirement has the industry worried other markets will demand lower prices.

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

Few employers contain specialty Rx costs: study

Few employers contain specialty Rx costs: study

By

The third Pharmacy Benefit Management Institute specialty medication survey expects specialty medications, which average around $3,000 per month per patient, will account for 50% of the drug spend within four or five years.

Gilead ponders Sovaldi price break

The drug maker is reportedly talking low rates for India's market.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

By

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

NICE gives Aubagio the nod

The price watchdog said Sanofi's oral MS drug Aubagio is a go. The decision follows a September directive to prove the drug's cost-effectiveness.

Patent cliff a drag on 2012 health spend

Patent cliff a drag on 2012 health spend

By

Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.

Antidepressants may have to fight for Part D coverage

CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

BMS pulls new diabetes med in Germany

The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.

Think tank says raise Rx prices for NHS

The National Health Service is expected to have a $49-billion deficit by 2020.

CVS says specialty drug spend to quadruple

CVS says specialty drug spend to quadruple

By

The PBM encourages step-therapy to control costs.

IMS predicts $1T global drug market by 2017

IMS predicts $1T global drug market by 2017

By

The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.

India's dual pricing pressures

Domestic manufacturers are being pressured to offer domestic discounts to international clients.

Pfizer picks fight with NICE

The drugmaker blasted the price-control agency for being shortsighted and underestimating the industry's role in health and savings.

Co-pay cards OK for exchanges

Subscribers will be able to use co-pay cards on Obamacare exchanges.

New York Magazine examines cancer drug pricing

New York Magazine examines cancer drug pricing

A wide-ranging piece recounts the pushback from oncologists that led to a decrease in the price of Zaltrap.

Can we handle cost of a healthy, aging population?

Can we handle cost of a healthy, aging population?

By

The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.

Business briefs: AbbVie, FDA, and health spending projections

AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011

CMS projects healthcare spending to rise

CMS projects healthcare spending to rise

By

Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards

Business briefs: CDC, Facebook, Shire

CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany

Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire

Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration

Business briefs: GSK, Otsuka, Roche and Gilead

GSK seeks a new ovarian cancer indication for Votrient; a bill that would extend exclusivity for some combination drugs is introduced in Congress; Otsuka's tolvaptan gets a thumbs-down from an FDA advisory committee; NICE rejects Roche's Perjeta; India tosses Herceptin patents; and China revokes Gilead's patent on Viread

Email Newsletters